Literature DB >> 26358083

Rubidium-82 uptake in metastases from neuroendocrine tumors: No flow response to adenosine.

Philip Hasbak1, Lotte Hahn Enevoldsen2, Marie Øbro Fosbøl2, Dorthe Skovgaard2, Ulrich Peter Knigge3,4,5, Andreas Kjær2,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26358083     DOI： 10.1007/s12350-015-0251-z

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  3 in total

1.  Extracardiac abnormalities on rubidium-82 cardiac positron emission tomography/computed tomography.

Authors:  Sahar Mirpour; Amir H Khandani
Journal:  Nucl Med Commun       Date:  2011-04       Impact factor: 1.690

2.  Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapy.

Authors:  A Kalhan; B Gharibi; M Vazquez; B Jasani; J Neal; M Kidd; I M Modlin; R Pfragner; D A Rees; J Ham
Journal:  Purinergic Signal       Date:  2011-11-27       Impact factor: 3.765

3.  Quantification of myocardial blood flow with 82Rb dynamic PET imaging.

Authors:  Mireille Lortie; Rob S B Beanlands; Keiichiro Yoshinaga; Ran Klein; Jean N Dasilva; Robert A DeKemp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-07-07       Impact factor: 9.236
  3 in total
  2 in total

1.  Rubidium Uptake in Chest Tumors on PET/CT.

Authors:  Jorge D Oldan; Abiola D Femi-Abodunde; Mitchel A Muhleman; Amir H Khandani
Journal:  World J Nucl Med       Date:  2022-02-24

2.  Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na+/K+-ATPase-density.

Authors:  Mads Ryø Jochumsen; Jens Sörensen; Bodil Ginnerup Pedersen; Jens Randel Nyengaard; Søren Rasmus Palmelund Krag; Jørgen Frøkiær; Michael Borre; Kirsten Bouchelouche; Lars Poulsen Tolbod
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-18       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.